In Science this week: approach to uncover recent changes in allele frequencies, and more.
Utah's Dana Carroll, UC Berkeley's Jacob Corn, and their colleagues replaced the sickle cell disease mutation with the wild-type gene via HDR.
Researchers describe using a CRISPR approach to edit the sickle cell gene in vitro, the Los Angeles Times reports.
In PNAS this week: work toward a CRISPR/Cas9-based approach to treat beta-thalassemia or sickle cell disease, bacteriophages uncovered in human stool, and more.
In Nature this week: Exome Aggregation Consortium analysis of some 60,000 exomes, and more.
Scientists introduced an indel to a promoter region to mimic a benign, naturally-occurring mutation that activated fetal hemoglobin production.
Protective genetic mutations are providing a blueprint for companies wanting to treat sickle cell, Scientific American reports.
The partners will focus on developing gene editing-based treatments for cystic fibrosis and sickle cell disease, among other diseases.
By editing a promoter of an enhancer of the mutated hemoglobin responsible for sickle cell disease, the researchers may have found a way to treat it.
Transforming Medicine: The Elizabeth Kauffman Institute plans to develop a knowledgebase for evaluating patient information, including genetic and molecular data.
National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.
In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.
Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.
According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.